Search clinical trials for: MOR00208 (formerly Xmab5574)

Total 196 results

MorphoSys AG

Terminated

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Acute Lymphoblastic Leukemia

United States
MorphoSys AG

Completed

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, Belgium, Germany, Hungary, Italy, Poland, Spain
Ohio State University Comprehensive Cancer Center
MorphoSys AG

Active, not recruiting

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Contiguous Stage II Small Lymphocytic... and other conditions

United States
MorphoSys AG

Recruiting

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway)

Diffuse Large B Cell Lymphoma

Korea, Republic of, Czechia, Spain, Israel, Italy, Austria, Poland, United States, France
Xencor, Inc.

Completed

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
University Hospital Tuebingen

Recruiting

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (Anti-CD19-ALL)

ALL, Childhood B-Cell | Acute Lymphoid Leukemia Relapse | Acute Lymphocytic Leukemia Refractory

Germany
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
IWK Health Centre
McGill University; Canadian Institutes of Health Research (CIHR); University... and other collaborators

Active, not recruiting

Strongest FamiliesTM Neurodevelopmental

Neurodevelopmental Disorders | Behavior Disorders

Canada
GlaxoSmithKline

Completed

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Carcinoma, Renal Cell

United States
GlaxoSmithKline

Completed

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Solid Tumours
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
IWK Health Centre
Canadian Institutes of Health Research (CIHR)

Completed

Strongest Families (Formerly Family Help Program): Pediatric Anxiety (FHP-ANX)

Anxiety Disorder

Canada
Digital Diagnostics, Inc.
The Emmes Company, LLC

Completed

A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy

Diabetic Retinopathy
Cinclus Pharma AG

Completed

Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation (BA)

Pharmacokinetics | Bioavailability | Safety

Slovenia
BrainQ Technologies Ltd.

Terminated

Efficacy of EMF BCI Based Device on Acute Stroke

Acute Stroke

India
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Multiple Myeloma | Non-Small Cell Lung Cancer | Solid Tumors

United States
NOCwatch International
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Clinical Evaluation of a Wireless Monitoring Device to Reduce Falls in the Elderly and Others at High Risk of Falling

Injuries | Fractures | Accidental Falls

United States
MorphoSys AG

Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, United Kingdom, Austria, Germany, Italy, Poland
IWK Health Centre
Canadian Institutes of Health Research (CIHR)

Completed

Strongest Families Ontario (Formerly the Family Help Program) (SF-ON)

Oppositional Defiant Disorder | Behaviour Disorder

Canada
Xencor, Inc.
Massachusetts General Hospital

Completed

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

IgG4-RD

United States
Xencor, Inc.
Parexel

Completed

XmAb5871 Bioavailability Study

Healthy Volunteers

United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis | Myasthenia Gravis

United States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
Columbia University
TG Therapeutics, Inc.

Terminated

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Reciprocal Labs
California HealthCare Foundation

Completed

Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System

Asthma

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
New York State Psychiatric Institute

Completed

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder (OCD)

United States
Hadassah Medical Organization
Nexcella, Inc

Recruiting

NXC-201 (Formerly HBI0101) Multiple Myeloma

Dose Escalation and Safety

Israel
Alexion

Completed

Study of ALXN2050 in Participants With Renal Impairment

Healthy | Renal Impairment

United States
Upstream Bio Inc.

Completed

Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults

Healthy

United Kingdom
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
IWK Health Centre
Canadian Institutes of Health Research (CIHR)

Completed

Strongest Families (Formerly Family Help Program): Pediatric Disruptive Behaviour Disorder

Pediatric Disruptive Behaviour Disorder

Canada
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

Marginal Zone Lymphoma

Italy, Switzerland, Austria
Columbia University

Terminated

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Hodgkin Disease | Lymphoma, Non-hodgkin

United States
Kibow Pharma

Recruiting

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

Chronic Kidney Disease stage4

United States
Alexion Pharmaceuticals

Completed

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Healthy

United States
University of Pennsylvania
Weight Watchers International

Completed

Neurocognitive Benefits of a Weight Management Program

Overweight and Obesity

United States
Shire

Completed

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

Healthy Volunteers

United States
ClearLine MD

Completed

Factors Increasing Air Burden in Intravenous Tubing

Air Leakage | Air Embolism | Air Burden
vTv Therapeutics

Completed

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Thallion Pharmaceuticals

Terminated

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

Melanoma

United States, Canada
Thallion Pharmaceuticals

Terminated

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

Glioblastoma Multiforme

United States, Canada
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
AstraZeneca

Completed

Baxdrostat Bioavailability and Bioequivalence Study

Hypertension

United States
Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Alexion Pharmaceuticals

Completed

Copper Balance in Healthy Participants Administered ALXN1840

Healthy

United Kingdom
Navire Pharma Inc., a BridgeBio company

Active, not recruiting

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Tumor, Solid

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of a Single Dose of Danicopan in Healthy Participants

Healthy

New Zealand
IWK Health Centre
Canadian Institutes of Health Research (CIHR)

Completed

Strongest Families (Formerly Family Help Program): Pediatric Attention Deficit/Hyperactivity Disorder (FHPADHD)

Attention Deficit/Hyperactivity Disorder

Canada

Search clinical trials for: MOR00208 (formerly Xmab5574)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations